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The success of medical therapy depends on the correct amount and the appropriate
delivery of the required drugs for treatment. By using biodegradable polymers a drug
delivery over a time span of weeks or even months is made possible. This opens up a
variety of strategies for better medication. The drug is embedded in a biodegradable
polymer (the “carrier”) and injected in a particular position of the human body. As a
consequence of the interplay between the diffusion process and the degrading polymer
the drug is released in a controlled manner. In this work we study the controlled release of
medication experimentally by measuring the delivered amount of drug within a cylindrical
shell over a long time interval into the body fluid. Moreover, a simple continuum model of
the Fickean type is initially proposed and solved in closed-form. It is used for simulating
some of the observed release processes for this type of carrier and takes the geometry
of the drug container explicitly into account. By comparing the measurement data
and the model predictions diffusion coefficients are obtained. It turns out that within
this simple model the coefficients change over time. This contradicts the idea that
diffusion coefficients are constants independent of the considered geometry. The model
is therefore extended by taking an additional absorption term into account leading to
a concentration dependent diffusion coefficient. This could now be used for further
predictions of drug release in carriers of different shape. For a better understanding of
the complex diffusion and degradation phenomena the underlying physics is discussed
in detail and even more sophisticated models involving different degradation and mass
transport phenomena are proposed for future work and study.
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Macha et al. Drug Delivery
1. INTRODUCTION
Over the years different drug carriers have been developed and
tested for drug delivery and targeting applications. In terms
of materials, polymers are the ones mostly used, perhaps due
to their simple forming properties in combination with easily
tunable properties. In drug release the release phenomenon varies
in complexity depending on the design and types of materials
involved. For polymeric materials the mechanisms of drug
release are normally directly linked to drug diffusion, dissolution,
and degradation of the carrier matrix. However, other factors,
such as interactions of the material and the drug, can also
influence the release kinetics. In addition to physicochemical
and morphological properties, the drug location within the
matrix, and the drug solubility are key parameters governing
the release kinetics and, therefore, the efficiency and efficacy of
the treatment. It has been suggested that degradable materials
could provide a steady and tunable release kinetics for different
therapeutic applications. Furthermore, it was postulated that the
use of combinatory materials for the design of drug release
systems has the potential for improving drug bioavailability
together with predictable release kinetics. Many efforts have been
directed toward the development of biodegradable composite
materials for drug delivery and targeted controlled release in
terms of reproducible and predictable release kinetics in order
to meet the therapeutic demands (Ginebra et al., 2006; Habibe
et al., 2009; Zhang et al., 2017; Li J. et al., 2018a,b; Li S. et al.,
2018; Zhang W. et al., 2018a,b; Zhang Y. et al., 2018). Previous
studies showed that bulk eroding polymeric materials show a
drug release pattern ranging from one stage (Schmidt et al.,
1995; Krasko et al., 2007; Billon-Chabaud et al., 2010; Morawska-
Chochółet al., 2014), three stages (Schnieders et al., 2006; Xu
and Czernuszka, 2008; Gosau and Müller, 2010) to four stages
(Shen et al., 2002; Takenaga et al., 2002). Further studies indicate
that the degradation mechanism greatly influences the controlled
release of the drug.
This study focuses on the release of gentamicin and clodronate
disodium bisphosphonate embedded or not in hydroxyapatite
within in a polylactic acid matrix. Similar systems have already
been used and are until now in the focus of medical interest
(e.g., for the case of gentamicin in Schmidt et al., 1995;
Kanellakopoulou and Giamarellos-Bourboulis, 2000; Friess and
Schlapp, 2002; Wang et al., 2004; Naraharisetti et al., 2005;
Schnieders et al., 2006; Krasko et al., 2007; Xu and Czernuszka,
2008; TorresGiner et al., 2012; Morawska-Chochółet al., 2014;
Shim et al., 2015; Dorati et al., 2016; and for bisphosphonate
in Billon-Chabaud et al., 2010; Su et al., 2011; Miladi et al.,
2013; Papathanasiou and Demadis, 2015; Aderibigbe et al.,
2016; Macha et al., 2017a,b; Sovány et al., 2017). It is fair
to say that these are experimentally oriented papers written
in the spirit of chemistry, biology, and medicine. They are
not theoretically oriented. In fact, experimentally obtained
release curves are often just presented and sometimes quantified
in terms of a very simple diffusion ansatz based on the
solution of the Fickean diffusion equation for a point source
(e.g., Brazel and Peppas, 2000; TorresGiner et al., 2012),
which does not truly take the effect of the carrier geometry
into account.
However, a considerable effort has also been made for
modeling the degradation-drug release behavior in these and
other drug carrying systems. One of the objectives is to
enable and to accompany a fast and rational design of
soluble drug release devices (see e.g., Lee, 1980; Brazel and
Peppas, 2000; Siepmann et al., 2002; Raman et al., 2005;
Arifin et al., 2006; Lao et al., 2008, 2011; Rothstein et al.,
2008, 2009, 2012; Siepmann and Siepmann, 2008; Dash et al.,
2010; Fredenberg et al., 2011; Kaunisto et al., 2011, 2013;
Siepmann and Peppas, 2012; Hines and Kaplan, 2013). In
order to improve the descriptions of drug release some of the
researchers included equations governing pore formation and
growth. Moreover, different geometries have been investigated
for drug release modeling. For example, thin film, spherical,
cubical, and cylindrical symmetries are frequently investigated
(Lao et al., 2008, 2011; Siepmann and Siepmann, 2008).
If the symmetry of the considered carrier proves to be high
then it becomes possible to reduce the simulation problem to
the solution of a transient partial differential equation with
one spatial dimension (e.g., Siepmann and Siepmann, 2008).
The corresponding numerical evaluation is relatively easy and
nowadays feasible with conventional computational power. In
the case of more complex situations, such as pore formation
and growth in the matrix, transport of the drug through an
embedding containment as a supply to the matrix (see below),
or for truly multi-dimensional geometries the controlled release
is more difficult to capture. Concretely this fact is a still a
weakness in modeling the drug release and we will discuss as well
as suggest further approaches for addressing such phenomena.
It is also a fair statement that the community of continuum
theoreticians and constitutive theorymodelers are not fully aware
of the need for capturing the drug release behavior in degrading
matrices mathematically.
This paper is a first preliminary attempt to create this
awareness. Initially experimental findings will be presented
and then correlated with an essentially analytical diffusion
model, which explicitly accounts for the underlying drug carrier
geometry and, hence, becomes more than just a curve fit. In fact
the predicted diffusion coefficients can be considered as geometry
independent and useful when assessing the release times from
other drug carriers of different geometry.
2. PHENOMENOLOGICAL DESCRIPTION
OF DRUG RELEASE
In this section the investigated drugs, their containment in
hydrolyzable, polymer-based matrices (the carriers), the involved
dissolution into a body-like fluid, and the corresponding
measurement of the drug concentration in that fluid as a function
of time will be described. It will be shown that various stages must
be distinguished and a (verbal) explanation for their occurrence
will be given.
2.1. Drugs, Drug Containing Materials, and
the Body Fluid Surrogate
In the experiments the dissolution behavior of two different
drugs was investigated, namely of GentaMicin (GM) and of
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TABLE 1 | Chemical composition of drugs and drug carrier matrix.
Name Chemical formula Molecular structure Molecular weight in g/mol Other properties
Gentamicin (drug 1) C21H43N5O7 477.6 Solubility in H2O: 50mg/ml
Clodronate disodium
bisphophonate (drug 2)
CH2Cl2Na2O6P2 287.85 Soluble in H2O
Polylactic acid (matrix) (C3H4O2)n 74250 Crystallinity ≈ 35%
clodronate disodium BisPhosphonate (BP). Some information
about their chemical properties can be found in Table 1. In
context with the follow-up comparison of diffusion coefficients
it is already now important to note that the BP has a smaller
molecular mass than the GM molecule. This will have an
impact on its migration capabilities through the matrix or, in
phenomenological terms, be reflected in the value of the diffusion
constant. This important fact has been emphasized before (e.g.,
in Makadia and Siegel, 2011).
Two different release media mimicking the body fluid were
used for dissolution and diffusion, i.e., phosphate buffered saline
solution for the GM and a tris-HCl buffer solution for the BP. The
reason for this choice was the procedure applied whenmeasuring
the concentration of the released drug, which was sensitive to
phosphorus (see the description in section 2.2). Both solutions
had a pH of 7.4 and were kept at a “body temperature” of 37
± 0.1◦C. The drugs were stored in a nanoporous matrix made
of PolyLactic Acid (PLA), either directly or first embedded in
HydroxylApatite (HAp). More specifically coralline HAp was
used, and the interested reader can find more information
on this topic in corresponding publications by the authors
(Ben-Nissan, 2003; Choi et al., 2014). The PLA matrix slowly
disintegrates and degrades in the solutions, thereby opening
more and more pore space for the drugs to release and also leave
their containment eventually.
Choosing a matrix without or with drug embedding and
two solutions led to four different experimental scenarios
with corresponding concentration measurements, namely
GentaMicin contained in PolyLactic Acid (PLA GM),
GentaMicin loaded in HydroxylApatite and then contained
in PolyLactic Acid (PLA HAp GM), BisPhosphonate contained
in PolyLactic Acid (PLA BP), and, finally, BisPhosphonate
(BP) loaded in HydroxylApatite (HAp) and then contained in
PolyLactic Acid (PLA HAp BP). We proceed to explain the
details of the measurements.
2.2. Experimental Procedure for Measuring
the Concentration of Released Drug
Drug loading to hydrothermally converted coralline HAp was
conducted in a vacuum controlled rotavapor with the appropriate
amount of either GM or BP mixed with HAp particles to give
10%w/w drug loading. The solution casting method was used
during the development of the polymer film composites (either
just enriched with the drug or with HAp loaded with drugs)
where the PLA was first dissolved in chloroform under room
temperature. Then it was mixed with drugs or HAp particles
under a magnetic stirrer. After that it was sonicated for 10min
and casted on a petri dish. The solvent in the casted samples
was allowed to evaporate under vacuum for 48 h. Finally a
thin polylactic acid composite film resulted, which was cut into
2 cm pieces, the thickness of which was around 0.2mm, cf.,
Figure 1, left.
Our assumption is that the drug is homogeneously distributed
within the containment. This is confirmed by the Scanning
Electron Micrograph (SEM) shown in Figure 2. The gray color
shows the PLA matrix, and the blisters consist of GM embedded
within the matrix. The distribution of the drug is fairly random
throughout the matrix, such that the probability of finding drug
at any point in the polymer matrix could be constant at all
positions within the matrix on the homogenized continuum level
of our future models.
The drug release was conducted in a buffer solution at a
volume large enough to provide complete dissolution of the
drug loaded in the samples. The concentration of drug in buffer
solutions was measured by using a UV-vis spectrophotometer
(Agilent Technologies, Australia) for GM. The quantification
of released BP was determined by using 31P-NMR (Agilent
Technologies, Australia).
The raw data of the current (average) concentrations of the
drug, c˜(t), were originally obtained in units of mg/ml, because by
definition the average concentration is given by
c˜(t) = m(t)
Vs
, (1)
where m(t) is the mass of drug at time t within the release
medium of volume, Vs. Note that the initial amount of drug in
thematrices wasmd = 7.5mg and the volume of the solution was
Vs = 15ml. Hence the maximum to-be-expected drug release
concentration could only be cmax = 0.5mg/ml. This information
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FIGURE 1 | Left: Film matrix specimens before and after curling; Right:
specimens in a tube.
could then be used to compute the fraction of drug released at
time t from the ratio
F(t) = c˜(t)
cmax
, 0 ≤ F(t) ≤ 1 (2)
in dimensionless units.
More specifically, the release medium in liquid form of
15ml was filled into FalconTM conical tubes of 17mm diameter
and 120mm length (see Figure 1, right). Note that the thin
film matrix specimens curled up to form cylindrical tubes
with a diameter in-between 0.5 and 0.65 cm. Hence they could
easily be accommodated in the FalconTM tube after an initial
slight bending. This was possible without breakage because the
films were quite flexible. At each time, t, 3 × 3 data points
for c˜ were taken: The contents of three tubes was examined
at every sampling time, such that they all were under the
same conditions. As indicated above the concentration values
were determined by measuring the absorbance in a UV-vis
spectrophotometer. A standard curve was used in this context.
It was constructed by using known concentration and measuring
the corresponding absorbance. Then the absorbance was plotted
against drug concentration resulting in a straight line curve.
Spectrophotometer cuvettes were used to store three samples
from each tube for the absorbance measurement. As required by
the spectrophotometer the cuvettes contained exactly 2ml. It is
fair to say that all nine readings per sampling time were very
similar, which explains the small error bars. The contents of each
tube was discarded after measurements. Each sampling time had
its own three tubes subjected to similar experimental conditions
according to the SINK conditions for drug release (SINK, 2009),
which require to maintain the release medium and do not allow
refills since this would affect the release kinetics.
2.3. Graphical Representation of Raw Data
The experimentally determined fraction of cumulative release,
F(t), for both drugs, GM and BP, are presented in Figures 3, 4,
respectively. In each case the influence of a containment for
the drug has also been recorded: pure PLA filled with drug vs.
PLA containing HAp with drug stored within. The continuous
FIGURE 2 | SEM of the drug containment.
FIGURE 3 | Fractional cumulative release of GM from PLA thin film composite
in PBS solution (pH 7.4, 37◦C and 100 rpm) for fifteen weeks. Error bars refer
to mean standard deviation of triplicate experimental data.
lines are (linear) interpolations between the measurement data
(squares). Error bars are indicated as well. In order to rule out
any measurement related discrepancies, two trial measurements
without drug were performed. From these it was concluded that
there was no GM present in the (initial) solution, as expected.
The different slopes in the plots indicate that it becomes
necessary to distinguish different stages of drug release due to
different physical phenomena. We will now attempt to give
reasons for the observed behavior based on the schematics shown
in Figure 5.
Evidently, the experiments with GM easily allow to distinguish
several different stages of drug release. In fact one can note
four different ones, identifiable by changes in slope or jumps in
slope in the release curve. In order to provide some physical
justification for this phenomenological observation, we argue
as follows:
• Stage I (week 1): In the case of the PLA GMmeasurements, we
observe initially a burst. This accelerated release is due to drug
particles situated on the outer surface of the matrix migrating
into the release medium. The illustration in the first top inset
of Figure 5 visualizes this phenomenon. For PLA HAp GM
the “burst” is less significant than for PLA GM. We explain
this fact as “configuration related,” this is to say related to the
confinement of the drug with theHAp. The drug—even if close
to the surface of the matrix—still has to tunnel through the
HAp and be supplied to the PLA-matrix, see the first bottom
inset in Figure 5.
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• Stage II (weeks 1–3): PLA GM continues to show a significant
release of drug, but the speed of release, i.e., the slope to the
F(t) curve does not show a jump. The polymermatrix will start
to degrade close to the surface and the corresponding drug
as well as some drug from further inside will be released, see
the second top inset in Figure 5. This behavior is analogous
for PLA HAp GM but not as pronounced, because of the
HAp, which must be overcome first to supply the drug, which
can then diffuse through the matrix, second bottom inset
in Figure 5. Also between week 2 and 3 a sudden burst is
observed. Some additional “production” of GM must be the
reason, maybe due to deterioration of the HAp embedding, at
least close to the surface.
• Stage III (weeks 3–5): Both PLA GM and PLA HAp GM show
a stagnation of drug release. One might think that the process
reaches an equilibrium. However, Stage 4 (see below) causes us
to develop another hypothesis. This lag phase can be explained
by the fact that the PLA matrix keeps degrading; but all of the
drug close to the surface has already been released, see the third
top and bottom insets in Figure 5.
• Stage IV (weeks 5–15): In both cases the polymer matrix
finally starts to show strong degrees of deterioration, pores
are forming through which the GM or the supply from the
HAp GM can more easily diffuse, see fourth top and bottom
insets in Figure 5. The experiments were stopped after week
15. Note that the release process in the case of PLA HAp GM
is much more pronounced as in the case of PLA GM. This
is due to the breaking of the HAp skeleton in addition to a
strongly deteriorating PLA matrix. This fact will affect our
future modeling.
In case of the BP experiments presented in Figure 4, no trial
measurements without drug were performed. The tests seem to
indicate a more or less continuous release of drug. In contrast
to GM at most three stages can be observed. The lag phase is
missing or not as pronounced, whichmay be due to the fact of the
different diffusion properties of the smaller BP molecules. More
specifically we note:
• Stage I (weeks 1 and 2): A strong burst of drug release is visible
in the case of PLA BP. The burst is much more pronounced
than for the case of PLA HAp BP, since in the latter
configuration it is necessary to overcome the additional HAp
barrier first and to supply drug to the polymer matrix. It also
shows that the drug release for PLA GM and PLA HAp GM is
less than for PLABP and PLAHApBP. Obviously the diffusion
in the two latter cases is easier, maybe due to the smaller size
of the BP drug molecules.
• Stage II (week 2–3): The drug release slows down in both cases,
this process can be related to an equilibrium condition. At the
same time, the formation of voids due to the degradation of
the matrix is on its way.
• Stage III (week 3–11): In both cases the formation of voids
and degradation of the matrix is sluggishly continuing in the
case of PLA BP and slightly faster for PLA HAp BP. No
strong jumps in the release speed were observed in this and all
other stages. This causes us to believe that the corresponding
solution fluid might be less aggressive.
FIGURE 4 | Fractional cumulative release of BP from PLA thin film composite
in TrisHCl buffer solution, pH 7.4, at 37◦C and 100 rpm for 11 weeks. Error
bars refer to mean standard deviation of replicate experimental data.
In summary we may say that the cases of PLA GM and PLA BP
should be describable by standard diffusion equations, whereas
in the case of PLA HAp GM and PLA HAp BP a more complex
simulation seems to be required. Here the standard diffusion
equation should be equipped by a supply term mimicking the
provision of drug from the HAp containment to the PLA matrix.
3. MODELING OF THE DIFFUSION
PROCESS
In this paper the emphasis will be on modeling the release
processes in context with drug exclusively stored in the PLA
matrix through which it diffuses, either slowly as long the
polymer stays intact, or more quickly when the polymer
gradually deteriorates and gives “more way” to the diffusing
drug molecules. More precisely, the results shown in the orange
curves of Figures 3, 4 will be quantified in terms of (time-
dependent) diffusion constants. The principles of the modeling
will be explained in the next subsection and then gradually be
made more concrete.
A quantification of the blue curves in both pictures is more
difficult, because the underlying physics should be observed in
the modeling. Here the drug has to diffuse first through the HAp
to enter the PLA matrix. In other words, the drug is supplied
to the matrix and after that it diffuses through the PLA into
the solution. The supply will be greater when the HAp starts to
deteriorate, but it is still a supply, which will be part of a modified
diffusion equation, but not in terms of an adjusted diffusion
coefficient of drug diffusing through the polymer matrix. Hence
this type of modeling will result in diffusion constants and in
parameters characteristic of the supply, i.e., the release of drug
into the polymer matrix. For the supply term in the diffusion
equation an adequate constitutive equation must be stated. The
idea is to base this relation on a micro-model for the drug
diffusion through an HAp shell. However, for conciseness of this
paper the corresponding quantification is left to future research.
3.1. Initial Remarks on the Principles of the
Modeling Procedure
Some remarks from the viewpoint of continuum physics are now
in order. Typically the concentration, c, is a field variable: c(x, t).
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FIGURE 5 | Illustration of release stages for GM without and with HAp.
In other words, unlike the measured data, c˜(t), it depends on
both time, t, and spacepoint, x. The experimentally determined
concentration was no true field. It was uniform within the
solution, because the test was conducted in a water bath
temperature controlled shaker at 100 rpm.
In our simulations we will study the diffusion within a thin
filmmatrix. The film is curled up in form of a cylindrical tube and
fully immersed in the solution. For this geometry we will solve a
transient diffusion equation of the form
∂c
∂t
= −∇ · J − d˙, (3)
where J(x, t) is the diffusion flux for which we use Fick’s first law,
J = −Dm∇c (4)
with the unknown diffusion coefficient of the drug in the matrix,
Dm, which is a true constant for an isothermal process. The mass
of the drug is conserved. Hence usually there is no drain term d˙.
However, we shall see that at later stages of the release process
a constant diffusion coefficient would lead to predictions for the
concentrations of drug in the solution higher than observed. For
this reason we assume that drug particles are absorbed in the
matrix, follow (Nestle and Kimmich, 1996) and write:
d˙ = ∂cb
∂t
, (5)
where cb is the concentration of the bound molecules, a.k.a.
the sorption isotherm. Based on fits to experimental data many
expressions have been proposed for sorption isotherms linking
them to the concentration c. We follow the proposition by
Temkin (see the list and reference in Table 1 of Nestle and
Kimmich, 1996),
cb = A ln(Bc), (6)
A and B being (constant) material parameters. It follows that:
∂c
∂t
= Deff1c, Deff =
c
c+ ADm. (7)
This is one of the simplest form of an effective diffusion
coefficient, Deff, which depends on the concentration itself.
It contains only one additional parameter, A, besides the
diffusion coefficient.
It should be mentioned that including a drain term in the
diffusion equation is not the only way to account for the fact that
the outflux of drugs stagnates at higher concentration levels in
the solution. Indeed, it is possible to put d˙ = 0 and to base the
model on boundary conditions of the Robin type:
∂ c˜(t)
∂t
= −α(c∗ − c˜(t))∇c · n, (8)
where n is the outward normal to the boundary surface.
Moreover, c∗ is the observed saturation level of the solution
concentration [to be read off from the experimental F(t) plot],
c˜(t), and α is the only remaining unknown material parameter
characteristic of the permeability of the matrix wall, which is at
the drug concentration level c. In engineering is also known as
the mass transfer coefficient.
The diffusion flux can be used to obtain the mass outflux of
drug, m˙(t), across the surfaces of the cylindrical tube, ∂Vcyl,
m˙(t) =
∮
∂Vcyl
J(x, t) · n dA, (9)
where dA is the surface element.
Hence the total mass of drug released into the solution follows
by integration in time from which the drug release can be
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FIGURE 6 | Illustration of the geometry.
calculated:
m(t) =
t˜=t∫
t˜=0
m˙(t) dt ⇒ F(t) = m(t)
Vscmax
. (10)
The unknown diffusion constant can now be determined
such that the predicted drug release agrees with the actually
observed average release fraction F(t), which is known from the
experiments. The necessary input data will be discussed shortly.
In the next subsections we present solutions to these various
initial boundary value problems. We will start with a closed form
solution for the concentration field c(x, t) at a point x within
the matrix tube. This expression contains the unknown diffusion
constant of the drug in the matrix, Dm, and takes the cylindrical
geometry explicitly into account. The advantage of this solution
is that everything can be evaluated analytically without taking
resource to advanced numerical methods.
3.2. Closed for Solution of a Simplified
One-Dimensional Diffusion Problem
It was mentioned above that the drug is released from a hollow
cylindrical tube, which formed by curling of a square thin film
(the “matrix”) of height h = 20mm and thickness d = 0.2mm
into a surrounding fluid (the “solution”) of volume Vs = 15ml.
Strictly speaking, this is a axisymmetric yet three-dimensional
problem, because of the finite height of the cylindrical tube,
which can only be treated numerically. However, even with
the appropriate tool, e.g., a finite element (FE) code, finite
volume (FV) or finite difference methods, it will result in a
model with a very high amount of degrees of freedom, in
particular because of the extremely thin cylinder wall, which
needs to be discretized very finely. Surely, such an approach is
prohibitive if the objective is a timely check of how a change
of matrix geometry (for example) would influence the release
time. Hence, it is beneficial to have a simplified simulation tool
at one’s disposal, which can be exploited without too much
computational effort—in other words, a model that allows for a
more or less analytical solution.
In this spirit we argue that the diffusion process from the
cylindrical tube into the solution takes place only in radial
direction and the transport in axial direction of the tube walls
to the solution can be ignored. This seems reasonable, because
the cylinder walls are so thin when compared to height of the
cylinder axis.
The ordinary Fickean diffusion equation for the concentration
field c follows from Equation (7) by putting k = 0. Then for
a purely radial dependence of the concentration the cylindrical
Laplace operator reads when applied to c(r, t):
1c = 1
r
∂
∂r
(
r
∂
∂r
)
= ∂
2c
∂r2
+ 1
r
∂c
∂r
. (11)
Wewill solve this equation only within the wall of a now infinitely
long cylindrical tube, i.e., within the region a = ri ≤ r ≤ b =
ri + d, where the inner radius is given by:
ri =
h
2pi
≈ 3.2mm. (12)
The initial concentration within the cylinder walls is a constant
and given by:
c0 =
md
pih
(
2rid + d2
) ≈ 90.9 mg
ml
. (13)
The situation is illustrated in Figure 6. This in combination with
∂c
∂t
= Dm
(
∂2c
∂r2
+ 1
r
∂c
∂r
)
, a ≤ r ≤ b, (14)
where Dm is the (unknown) diffusion coefficient in the matrix,
forms the skeleton of our initial-boundary-value-problem. The
question remains, which boundary conditions to employ. To this
end it is argued as follows. First, assume that the diffusion within
the liquid is much faster than within the solid matrix, which
seems reasonable. Then conclude that the flux of mass leaving the
solid at the boundaries is immediately distributed evenly within
the solution, inside and outside of the cylinder, because in the
real experiment these regions are connected anyway. Following
Equation (4) one may say that, in general, the flux in a purely
radial cylindrically symmetric problem is given by
J = −Dm
∂c
∂r
er . (15)
Hence the total output of mass per unit time across the
boundaries at a and b reads
m˙(t) = h2piDm
(
∂c
∂r
∣∣∣∣
r=a
a− ∂c
∂r
∣∣∣∣
r=b
b
)
. (16)
This will lead to a rise of drug concentration in the solution of
dc = m˙dt/Vs and we may conclude that the concentration at the
boundaries is a function of time and given by
c(t) = 1
Vs
t˜=t∫
t˜=0
m˙(t) dt. (17)
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In fact, if we divide this expression by cmax we obtain the drug
release function F(t) defined in Equation (2) and numerical
values for this function are known from the experiments shown
in Figures 3, 4. This concludes detailing the relations shown in
Equations (9)–(10) for the case of a cylindrical tube, the axis of
which is much longer than the thickness of its walls. Hence all
that remains is to find a solution of the diffusion Equation (14)
with time-dependent boundary conditions:
c(r = a, t) = F(t)cmax , c(r = b, t) = F(t)cmax. (18)
To find this solution is unfortunately also a numerical task.
However, if the boundary conditions are time-independent and
given by the value cw (see Figure 6), an analytical solution of the
cylinder symmetric diffusion problem was presented in Carslaw
and Jaeger (1959, p. 205), section 7.10, based on Bernoulli’s
method of the separation of variables, here r and t. Rewritten for
our purposes it reads
c(r, t) = cw + pi (c0 − cw)
∞∑
n=1
J0 (αn)U0
( r
aαn
)
J0 (αn)+ J0
(
kαn
) exp
(
−Dmα
2
n
a2
t
)
,
(19)
where
U0
(
r
aαn
)
: = J0
(
r
aαn
)
Y0
(
kαn
)− J0 (kαn)Y0 ( raαn) , k : = ba ,
(20)
and c0 is the initially constant concentration within the wall of
the cylindrical tube. J0 and Y0 are Bessel functions of the first and
second kind of zeroth order. The coefficients αn are roots to the
following transcendental equation
U0 (αn) = 0. (21)
They must be found numerically. It turns out that for our case
of a very thin wall, k ≈ 1.063, they are very large. A numerical
investigation using Mathematica shows that αn ≈ 50 n. This
means in practice that, because of the exponential, we can already
cut off the infinite series after the first term. It also facilitates
getting an estimate for the diffusion data, as we shall see shortly.
To begin with we use the solution shown in Equation (19) in
context with Equation (16) to find the mass rate
m˙(t) = 4pihDm (c0 − cw)
∞∑
n=1
J0 (αn)− J0
(
kαn
)
J0 (αn)+ J0
(
kαn
) exp
(
−Dmα
2
n
a2
t
)
.
(22)
During the derivation of this formula use was made of
the relations(
r
dU0
dr
) ∣∣∣∣
r=a
= − 2
pi
J0
(
kαn
)
J0 (αn)
,
(
r
dU0
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) ∣∣∣∣
r=b
= − 2
pi
. (23)
Since during the derivation of Equation (22) cw and Dm were
assumed to be constant, the expression can easily be integrated
over a time interval tm ≤ t ≤ tm+1:
m(tm+1)−m(tm) = 4piha2 (c0 − cw)×
∞∑
n=1
J0 (αn)− J0
(
kαn
)
α2n
[
J0 (αn)+ J0
(
kαn
)] [exp(−Dmα2n
a2
tm
)
− exp
(
−Dmα
2
n
a2
tm+1
)]
.
(24)
Equation (24) forms the basis for our numerical assessment in the
next section.
3.3. Evaluation of the Simplified
One-Dimensional Model and Comparison
With the Literature
Table 2 presents the numerical drug release data for GM in PLA
shown in the orange curve of Figure 3. They will now be used
to obtain an approximative value for the constant of diffusion,
depending upon the considered time interval between time step
m to time stepm+1. Assume that cw = cw(tm). Then we evaluate
(24) in a discretized fashion as follows and find for the increase
in drug release in the time interval tm ≤ t ≤ tm+1:
F(tm+1) = F(tm)+
4piha2
Vs
c0−cw(tm)
cmax
∞∑
n=1
J0(αn)−J0(kαn)
α2n[J0(αn)+J0(kαn)][
exp
(
−Dmmα2n
a2
tm
)
− exp
(
−Dm+1m α2n
a2
tm+1
)]
, (25)
where Dm+1m is an update to the diffusion coefficient at the time
Dmm. Recall that the drug release data F(tm+1) and F(tm) are
known from the experiments: Table 2.
We are now in a position to compute an update for the
diffusion coefficient:
Dm+1m = −
a2
α21 tm+1
ln
[
exp
(
−D
m
mα
2
1
a2
tm
)
−
[
F(tm+1)− F(tm)
] Vs
4piha2
cmax
c0 − cw(tm)
α21
[
J0 (α1)+ J0
(
kα1
)]
J0 (α1)− J0
(
kα1
)
]
.
(26)
For this purpose we have terminated the sum after the first term.
This is possible because of the large values of αn. The starting
value for the diffusion coefficients is zero, D0m = 0, because
there is no diffusion before week 0. The diffusion coefficients
resulting for weeks 1 through 5 are indicated by the red dots in
Figure 7. A time-dependence accompanied by a steady decrease
can be observed, which one may want to interpret intuitively
as an inhibition of diffusion, because the difference c0 − cw(tm)
becomes smaller and smaller as time progresses. However, as the
discussion below will show, this interpretation should be taken
with a grain of salt.
Now that the diffusion coefficients are known the progression
of drug release can be calculated from the following formula:
Fm+1(t) = Fm(tm)+
4piha2
Vs
c0 − cw(tm)
cmax
∞∑
n=1
J0 (αn)− J0
(
kαn
)
α2n
[
J0 (αn)+ J0
(
kαn
)]×
[
exp
(
−D
m
mα
2
n
a2
tm
)
− exp
(
−
[(
Dm+1m tm+1 − Dmmtm
) t − tm
tm+1 − tm
+ Dmmtm
]
α2n
a2
)]
,
(27)
where tm ≤ t ≤ tm+1. Note that in practice it is not
necessary to carry out the summation beyond n = 1. In order
to introduce a continuous time dependency, the updated drug
release is modified, Fm+1(tm+1) → Fm+1(t), and the product
Dm+1m tm+1 in Equation (25) is replaced by a linear interpolation
between the time steps tm and tm+1. The perfect agreement for
weeks 1 through 5 is shown in Figure 8.
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TABLE 2 | GM in PLA.
Week m 0 1 2 3 4 5 7 8 9 11 15
F (tm) 0.0 0.399 0.517 0.607 0.623 0.639 0.792 0.805 0.814 0.823 0.844
FIGURE 7 | The time dependence of diffusion coefficients for GM in PLA.
FIGURE 8 | Drug release predicted (blue curve) for GM in PLA in comparison
with measurement data (red dots).
After week 5 the last diffusion coefficient was used to predict
the drug release if there were no change in the releasemechanism.
This is indicated by the dashed blue line. Clearly the prediction
does not match the actually observed data. Indeed, it has already
been noted that after that time the matrix deteriorates strongly.
Consequently, a different evaluation strategy for the diffusion is
required. In fact, it is still based on Equation (26) with three
subtle differences. First, c0 was replaced with a concentration
value based on the amount of drug remaining in the matrix after
the release through weeks 1 through 5. Strictly speaking, the
concentration profile is no longer constant within ri ≤ r ≤ ri+d.
However, d is so small that this variation can be neglected and the
solution for a constant initial concentration be reused. Second,
the diffusion started anew, i.e., a diffusion coefficientDm = 0 was
used at time tm =week 5 and, third, F(tm = week 5) = 0.639 was
used as starting value for the drug release.
The resulting diffusion coefficients are indicated by the green
dots in Figure 7. They also decrease steadily over time and
a jump when compared to the last red dot is clearly visible,
which is indicative of the change in diffusion mechanism. An
accordingly adjusted version of Equation (27) was then used to
predict the drug release during weeks 5 through 11, which is
shown in Figure 8.
A word of caution is finally in order. Note that there are no
physical reasons that the diffusion coefficient decreases during
the release process in weeks 1 through 5 and then, after the jump,
oncemore in weeks 5 through 15. The diffusion coefficient should
simply remain constant during these two time intervals. Its time-
dependent behavior must be attributed to the fact that constant
concentrations cw were used for boundary conditions during
the discretization steps, whereas in reality the concentration at
the boundary, cw(t), is time-dependent and steadily growing,
so that the difference c0 − cw(t) becomes smaller over time.
Hence the driving force for diffusion, J, actually decreases in
magnitude because of a lack in concentration gradient and not
because of a time-dependent diffusion constant (see Equation
(4)). This is an artifact of our way of simulation and due
to the chosen closed-form solution, which does not allow for
time-dependent concentrations at the cylinder walls. The only
physically meaningful conclusion one may draw from Figure 7
is that there is a boost in drug release at week 5, due to the heavily
deteriorated matrix. If one so wishes the diffusion coefficients
during weeks 1 through 5 and 5 through 15 can be averaged
to obtain ballpark number for describing the diffusion before
and after matrix deterioration, D¯1−5m ≈ 3.12 × 10−9mm2/s and
D¯5−15m ≈ 1.28× 10−9mm2/s. However, by doing this one loses the
aspect of the boost in drug release after week 5.
Performing a comparison between our diffusion coefficients
for GM in PLA is not as straightforward as one wishes it to be,
mainly for two reasons. First, the diffusion data in the literature
are often obtained by fitting release curves with the point source
solution of the Fickean diffusion equation (see e.g., Crank, 1979,
p. 11), i.e., a
√
t-fit, which is geometry dependent and, second, the
matrix chosen for GM is not PLA.
In Dunn et al. (1981, p. 137) values for the product DCs
are shown, where D is the diffusion coefficient and Cs is the
saturation solubility. For poly (DL-lactide) a value DCs = 6.4 ×
10−13 gcm s is presented. If the saturation solubility is assumed to
be equal to c0 a diffusion constant of roughly 7.0 × 10−9 mm
2
s is
obtained, which is of the same order as our values.
In Table 1 from Zhang et al. (1995) the release of GM
from poly(DL-lactide) full cylinders of various heights, L, was
investigated and resulted in what the authors called “effective”
diffusion coefficients, Deff, for this particular geometry
1. By
1Not to be confused with Deff from Equation (7).
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comparing the exponentials showing the temporal evolution for
the full cylinder geometry and for the solution used in this paper,
one comes to the conclusion that:
Dm =
pi
2r2i
L2α21
Deff. (28)
This conversion formula was applied to the data leading to the
values shown in Table 3. Hence most of the values agree with the
findings of this paper.
Table 4 contains the numerical data for the release of BP
within PLA as shown in the orange curve of Figure 4. In Figure 9,
the results for the corresponding diffusion constants and release
predictions are presented, analogously as in the case of GM,
Figures 7, 8. The same words of caution apply as in context with
Figure 7: The time-dependence of the diffusion constants does
not have a physical meaning. Rather it is an artifact of the closed-
form solution used, which does not allow for time-dependent
boundary conditions. However, we may say that tendentially
the diffusion constants (left inset of the figure) are now higher
because the drug molecule is smaller. And what is more, there
is no abrupt jump of the diffusion coefficients after some weeks.
Moreover, the fact that the first and ninth diffusion coefficient in
the left inset of Figure 9 show some unsteady behavior should
be attributed to the discretized fitting procedure and also not be
regarded as a physical effect. In fact note that at high times the
slope of the drug release curve becomes quite shallow, which is a
problem for the applied discrete evaluation technique. But finally,
as in the case of GM, an excellent agreement for the predicted
release rates with the experimental measurements (inset on the
right) can be observed.
A comparison of our diffusion constants for BP in PLA
with values from the literature is very difficult, since despite
an intensive search such data seems currently not to be
available. Billon-Chabaud et al. (2010) present experimental
release curves of BP from various carriers but do not evaluate
them mathematically. Based on studies of the C14 migration of
zoledronate through trabecular bone (Stadelmann et al., 2009)
report an estimate for a diffusion coefficient of 9.3 × 10−9 mm2s ,
TABLE 3 | Diffusion coefficients Dm in units of 10
−9 mm2
s as a function of drug
loading converted from data in Zhang et al. (1995).
L [mm] 20 wt% 30 wt% 40 wt% 50 wt%
2 - 4.8 - -
4 - 1.7 - -
5 1.0 1.3 11.1 73.9
7 - 1.5 - -
10 - 1.0 4.1 41.1
20 - - 1.6 31.4
TABLE 4 | BP in PLA.
week m 0 1 2 3 4 5 7 8 9 10 11
F (tm) 0.0 0.394 0.728 0.774 0.789 0.795 0.799 0.803 0.806 0.809 0.811
which despite the different medium is of the same order of
magnitude as our data.
3.4. Numerical Solutions of the Diffusion
Problems
The apparent time-dependence of the diffusion coefficients
shown in Figures 7, 9 has already been critically examined
and interpreted as an artifact due to somewhat artificial
realization of the boundary condition at the interface between
the matrix and solution. The latter was based on a discontinuous
fit of the observed values for F(t). It was mentioned that
continuous boundary conditions cannot be captured within
the framework of an analytical solution, such as the one
shown in Equation (19) and numerical methods have to be
employed. An FE study2 of the one-dimensional problem has
therefore been performed with the objective to describe the
temporal development of F(t) by means of a single value for
the diffusion parameter Dm. To this end, the discrete data
F(ti) were interpolated linearly. The diffusion Equation (14)
was solved repeatedly by changing the diffusion coefficient in
combination with a Gauss mean square target function for
the predicted and measured release data. The result is shown
in Figure 10.
We found for GM that Dm = 1.47 × 10−9 mm
2
s and Dm =
0.66 × 10−9 mm2s for the first 5 weeks and after that, respectively,
andDm = 2.22×10−9 mm
2
s for BP. The least mean square error is
around 2.5%, 1.3%, and 3.6% and therefore quite high. This is also
indirectly visible in the plots when the predictions (solid lines)
are compared to the measurements (red dots). Similarly as in the
case of the averaged time dependent diffusion coefficients shown
in Figure 7 the value of Dm decreases after the first 5 weeks when
the diffusion is more impeded. However, the absolute numbers
are now smaller.
We now turn to the solution of the diffusion equation when
using the effective concentration dependent diffusion coefficient
according to Temkin, Equation (7). After using the same FE and
optimization techniques as before we obtained the results shown
in Figure 11. We found for GM Dm = 3.91 × 10−9 mm
2
s ,A =
2.66 × 10−3 mg
ml
and Dm = 3.69 × 10−9 mm
2
s ,A = 3.97 ×
10−3 mg
ml
, respectively, and for BP Dm = 4.15 × 10−9 mm
2
s ,A =
1.03 × 10−3 mg
ml
. Note that during the two stages of the GM
release the A value changes. This is reasonable to assume because
the absorption properties will change when the matrix structure
alters. In fact absorption is increasing, as one could surmized
by looking at the concentration data, which saturate earlier than
anticipated. A decreasing value ofA is in agreement with this. It is
also interesting to note that the diffusion coefficient stays almost
at the same level. Also, the agreement between predictions and
measured data is nowmuch better. Indeed, the least mean square
errors of the predicted and the observed release values are 0.4,
0.2, 1.4 percent, respectively. The Dm of BP is also greater than
those for GM, which corresponds to the smaller size of the drug
2The technical details of that study as well as the FV analysis mentioned further
below will be published elsewhere.
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FIGURE 9 | Diffusion coefficients (Left) and drug release predicted (Right, blue curve) for BP in PLA in comparison with measurement data (red dots).
FIGURE 10 | Predicted fractional release based on constant diffusion coefficients for GM (Left) and BP (Right).
FIGURE 11 | Predicted fractional release based on effective diffusion coefficients (Temkin model) for GM (Left) and BP (Right).
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FIGURE 12 | Predicted fractional release based on the Robin boundary condition (8) for GM (Left) and BP (Right).
molecule. Its absolute value is in agreement with theDm(t)-values
at later stages shown Figure 9.
Finally Equations (3), (4) were solved (with d˙ = 0) within the
cylindrical region in combination with the boundary condition
(8) based on an FV technique. The results are shown in Figure 12.
A first analysis predicted diffusion coefficients for GM of
Dm = 2.33 × 10−9 mm
2
s for the whole time span. However, the
coefficient α varied between 0.04 mlmg , for the first five and 0.02
ml
mg
for the remaining weeks, respectively, while c∗ = 0.425 mg
ml
. This
seems reasonable because the transfer is impeded after 5 weeks.
α plays a similar role as A in the case of Temkin’s concentration
dependent diffusion coefficient. They are inverse to each other, so
to speak. A full scale optimization analysis is currently underway,
which might give a result similar to the one found for GM during
the FE-calculations. In other words the Dm might prove to be
almost equal during the two time zones, while the values of α
are not. For BP we found Dm = 4.27 × 10−9 mm
2
s , α = 0.1,
c∗ = 0.4 mg
ml
. This is of the same magnitude as in the case of
the FE-investigations.
4. CONCLUSIONS AND OUTLOOK
Marine structures can play a vital role in the treatment of a wide
range of human diseases including non-curable one by providing
hydrothermally converted coralline HAp for drug loading and
release within a polymer-based matrix. In drug delivery, they
have demonstrated a potential for a controlled release of clinically
active agents. Their combination with degradable polymers in
terms of a drug containment facility supplying the drug in a
controlled manner to the polymer and then finally to the body
fluid has widened their application in orthopedics as implant
coatings for the prevention of biofilm.
In this paper experimental results have been presented
showing the release behavior without and with such HAp
containments. Moreover, the establishment of a quantitative
drug release kinetics model can help to speed up the controlled
drug release systems manufacturing. Knowing and quantitatively
describing the complexity of mechanisms will lead to mastering
the release from these devices.
For this reason, a collaborative effort between materials
scientists and continuum physicists has been made for the
development of a physically sound and closed-form release
model, presently only for the case without HAp containment. The
experimental results presented in this paper have been careful
considered and related to the theoretical aspects in this model
incorporating diffusion and degradation of the polymer matrix.
Quantitative results for time-dependent diffusion coefficients in
a degrading polymer matrix were presented based on this closed-
form 1D diffusion model for a thin film curled up to form
a thin-walled cylinder. The non-physical nature of the time-
dependence was discussed and average values for the diffusion
coefficients were compared to former literature data. In addition
first numerical investigations, based on FE and FV methods
were presented, which confirmed the average values of the time-
dependent diffusion coefficients from the analytical model. The
presented diffusion coefficients can be considered as geometry
independent and they are ready for predicting the release kinetics
in other geometries but thin film, for instance, fine structures
made from 3D polymer printing. These are in preparation by
the authors.
In the future the following remains to be done: First, the
presented cylindrical solution model should be evaluated for
a continuous input of drug concentrations at the cylinder
wall over time from a deteriorating PA matrix as well as
HAp containment. More precisely: This will require even more
detailed numerical analyses, based on finite element, finite
volume, or finite difference methods. The development of such
tools is currently underway and will result in time-independent
diffusion coefficients covering the time span until massive
degradation of the polymer matrix and for times after. It can be
expected that the (time-dependent) diffusion constants obtained
in this work will serve as good starting values for the iteration
procedure involved in the numerical approach. Ideally, a micro-
model leading to a constitutive equation for a supply term of drug
to the polymer matrix should be developed and then be included
in an extended diffusion equation. This relation will have be
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solved numerically with suitable initial-boundary value data. This
would allow to study the effect of a HAp containment supplying
drug to the polymer matrix. In a third step this constitutive
relation must be extended to account also for the deterioration
of the HAp container requiring further numerical analysis. The
general idea is to separate the various physical mechanisms and to
obtain physically meaningful, geometry independent parameters
by linking such models to experimental observations.
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